Silverarc Capital Management’s Sionna Therapeutics SION Stock Holding History

Silverarc Capital Management’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Buy	42,478 +3,061	+8%	+$122K	0.19%	62
2026 Q1	$1.58M	Sell	39,417 -2,043	-5%	-$78K	0.16%	62
2025 Q4	$1.71M	Sell	41,460 -67,341	-62%	-$2.55M	0.24%	58
2025 Q3	$3.2M	Sell	108,801 -77,214	-42%	-$1.68M	0.43%	54
2025 Q2	$3.23M	Buy	186,015 +71,877	+63%	+$942K	0.6%	40
2025 Q1	$1.19M	Buy	+114,138	New	+$1.86M	0.24%	59

Other funds holding SION

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Silverarc Capital Management's SION Position: Q2 2026 in Review

Silverarc Capital Management increased its Sionna Therapeutics (SION) stake by 7.8% in Q2 2026, buying an estimated $122K and bringing the position to 42,478 shares worth $1.87M. The position accounts for 0.19% of the portfolio, ranked #62.

Silverarc Capital Management first reported a position in SION in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.23M in Q2 2025. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

Silverarc Capital Management held 42,478 shares of Sionna Therapeutics worth $1.87M as of Q2 2026.
Silverarc Capital Management bought 3,061 Sionna Therapeutics shares in Q2 2026, an estimated $122K.
Sionna Therapeutics made up 0.19% of Silverarc Capital Management's portfolio in Q2 2026, its #62 holding.
Silverarc Capital Management first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
Silverarc Capital Management's Sionna Therapeutics position peaked at $3.23M in Q2 2025.
146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.